19 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Pharmaceutical company, Boehringer Ingelheim has established the foundation of veterinary vaccine manufacturing plant at China Medical City in Taizhou China Medicine High-Tech Development Zone, with an investment of $77.3 million. The facility is expected to complete construction in June 2015 and to create about 200 job opportunities.
Dr Joachim Hasenmaier, member, board of directors, who is also responsible for animal health, said, "China is one of the most important animal health markets in the world. With the start of this project, we are fulfilling our commitment to providing the entire value chain of our vaccine business in China.
He also added, "Taizhou China Medical City, with its favourable geographic location, sound investment environment and well qualified employees, among many other advantages, proved to be an ideal partner for Boehringer Ingelheim. The project underlines our commitment of continued investment in China."
Mr Lu Chunyun, standing committee member, Taizhou municipal government and president of China Medical City, said, "Boehringer Ingelheim is a leading player in the world's animal health sector, particularly in swine vaccines. China Medical City is the country's only national-level medical high-tech development park. This co-operation is set to create synergy and a win-win situation."
"Boehringer Ingelheim's vision is to become a reliable partner of choice for China's animal breeders and to contribute to food safety in China," said Dr Hasenmaier. "The animal health business together with our other strategic pillars, including prescription medicines, consumer healthcare, biopharmaceuticals and operations will continue to bring more health to China."